外科理论与实践 ›› 2021, Vol. 26 ›› Issue (06): 568-572.doi: 10.16139/j.1007-9610.2021.06.022
• 综述 • 上一篇
杨哲宇, 陆骋豪(综述), 蔡伟(审校)(
)
收稿日期:2020-05-25
出版日期:2021-11-25
发布日期:2022-07-27
通讯作者:
蔡伟(审校)
E-mail:caiwei@shsmu.edu.cn
基金资助:
YANG Zheyu, LU Chenghao, CAl Wei()
Received:2020-05-25
Online:2021-11-25
Published:2022-07-27
Contact:
CAl Wei
E-mail:caiwei@shsmu.edu.cn
中图分类号:
杨哲宇, 陆骋豪(综述), 蔡伟(审校). 浆细胞样树突状细胞与肿瘤免疫研究的新进展[J]. 外科理论与实践, 2021, 26(06): 568-572.
YANG Zheyu, LU Chenghao, CAl Wei. Recent advances in study on plasmacyloid dendritic cell and tumor immunity[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 568-572.
图1
pDC激活快速产生IFN-α的机制模型[15] A：pDC自我应答模型;B：pDC的协同表达模型
图2
pDC在肿瘤发病机制中的作用[12]
| [1] | Lennert K, Remmele W. Karyometric research on lymph node cells in man. I. Germinoblasts, lymphoblasts & lymphocytes[J]. Acta Haematol, 1958, 19(2):99-113. |
| [2] | O′Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature[J]. Immunology, 1994, 82(3):487-493. |
| [3] | Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand[J]. J Exp Med, 1997, 185(6):1101-1112. |
| [4] | Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood[J]. Science, 1999, 284(5421):1835-1837. |
| [5] | Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type Ⅱ C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction[J]. J Exp Med, 2001, 194(12):1823-1834. |
| [6] | Båve U, Magnusson M, Eloranta ML, et al. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α-Production induced by apoptotic cells combined with lupus IgG[J]. J Immunol, 2003, 171(6):3296-3302. |
| [7] | Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells[J]. Nat Rev Immunol, 2015, 15(8):471-485. |
| [8] | Shortman K, Sathe P, Vremec D, et al. Plasmacytoid dendritic cell development[J]. Adv Immunol, 2013, 120:105-126. |
| [9] | Rodrigues PF, Alberti-Servera L, Eremin A, et al. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells[J]. Nat Immunol, 2018, 19(7):711-722. |
| [10] | Schmid M, Kingston D, Boddupalli S, et al. Instructive cytokine signals in dendritic cell lineage commitment[J]. Immunol Rev, 2010, 234(1):32-44. |
| [11] | Waskow C, Liu K, Darrasse-Jèze G, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell develop-ment in peripheral lymphoid tissues[J]. Nat Immunol, 2008, 9(6):676-683. |
| [12] | Koucky V, Bouček J, Fialová A. Immunology of plasmacytoid dendritic cells in solid tumors: a brief review[J]. Cancers (Basel), 2019, 11(4):470. |
| [13] | Seth S, Oberdörfer L, Hyde R, et al. CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions[J]. J Immunol, 2011, 186:3364-3372. |
| [14] | Yu X, Cai B, Wang M, et al. Cross-regulation of two type I interferon signaling pathways in plasmacytoid dendritic cells controls anti-malaria immunity and host mortality[J]. Immunity, 2016, 45(5):1093-1107. |
| [15] | Reizis B. Plasmacytoid dendritic cells: development, re-gulation, and function[J]. Immunity, 2019, 50(1):37-50. |
| [16] | Honda K, Ohba Y, Yanai H, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-Ⅰ interferon induction[J]. Nature, 2005, 434(7036):1035-1040. |
| [17] | Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases[J]. Nat Rev Immunol, 2008, 8(8):594-606. |
| [18] | Kawasaki T, Kawai T. Toll-like receptor signaling pathways[J]. Front Immunol, 2014, 5:461. |
| [19] | Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, et al. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms[J]. Cell Host Microbe, 2014, 15(4):413-423. |
| [20] | Sasai M, Linehan MM, Iwasaki A. Bifurcation of toll-Like receptor 9 signaling by adaptor protein 3[J]. Science, 2010, 329(5998):1530-1534. |
| [21] | Blasius AL, Arnold CN, Georgel P, et al. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells[J]. Proc Natl Acad Sci U S A, 2010, 107(46):19973-19978. |
| [22] | Saitoh SI, Abe F, Kanno A, et al. TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells[J]. Nat Commun, 2017, 8(1):1592. |
| [23] | Tomasello E, Naciri K, Chelbi R, et al. in vivo Molecular dissection of plasmacytoid dendritic cell activation during a viral infection[J]. EMBO J, 2018, 37(19):e98836. |
| [24] | Ito T, Kanzler H, Duramad O, et al. Specialization, kine-tics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells[J]. Blood, 2006, 107(6):2423-2431. |
| [25] | Panda SK, Kolbeck R, Sanjuan MA. Plasmacytoid dendritic cells in autoimmunity[J]. Curr Opin Immunol, 2017, 44:20-25. |
| [26] | Sozzani S, Vermi W, Prete AD, et al. Trafficking properties of plasmacytoid dendritic cells in health and disease[J]. Trends Immunol, 2010, 31(7):270-277. |
| [27] | Guillerey C, Mouries J, Polo G, et al. Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice[J]. Blood, 2012, 120(1):90-99. |
| [28] | Vermi W, Soncini M, Melocchi L, et al. Plasmacytoid dendritic cells and cancer[J]. J Leukoc Biol, 2011, 90(4):681-690. |
| [29] | Han N, Zhang Z, Liu S, et al. Increased tumor-infiltrating plasmacytoid dendritic cells predicts poor prognosis in oral squamous cell carcinoma[J]. Arch Oral Biol, 2017, 78:129-134. |
| [30] | Sisirak V, Faget J, Gobert M, et al. Impaired IFN- production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression[J]. Cancer Research, 2012, 72(20):5188-5197. |
| [31] | Labidi-Galy S, Treilleux I, Goddard-Leon S, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis[J]. Oncoimmunology, 2012, 1(3):380-382. |
| [32] | Bruchhage K, Heinrichs S, Wollenberg B, et al. IL-10 in the microenvironment of HNSCC inhibits the CpG ODN induced IFN-α secretion of pDCs[J]. Oncol Lett, 2018, 15(3):3985-3990. |
| [33] | Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer[J]. Cancer Research, 2004, 64(16):5535-5538. |
| [34] | Labidi-Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer[J]. Cancer Res, 2011, 71(16):5423-5434. |
| [35] | Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma[J]. Cancer Res, 2005, 65(12):5020-5026. |
| [36] | Conrad C, Gregorio J, Wang YH, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells[J]. Cancer Res, 2012, 72(20):5240-5249. |
| [37] | Huang X, Liu X, Lin X, et al. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer[J]. Cancer Sci, 2014, 105(2):150-158. |
| [38] | Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors[J]. OncoImmunology, 2015, 4(6):e1008355. |
| [39] | Shi W, Li X, Porter JL, et al. Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma[J]. Tumor Biol, 2014, 35(3):2247-2252. |
| [40] | Sorrentino R, Morello S, Luciano A, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma[J]. J Immunol, 2010, 185(8):4641-4650. |
| [41] | Faith A, Peek E, Mcdonald J, et al. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses[J]. Am J Respir Cell Mol Biol, 2007, 36(3):360-367. |
| [42] | Aspord C, Leccia MT, Charles J, et al. Melanoma hijacks plasmacytoid dendritic cells to promote its own progression[J]. OncoImmunology, 2014, 3(1):e27402. |
| [43] | Aspord C, Leccia MT, Charles J, et al. Plasmacytoid dendritic cells support melanoma progression by promo-ting Th2 and regulatory immunity through OX40L and ICOSL[J]. Cancer Immunol Res, 2013, 1(6):402-415. |
| [44] | Montler R, Bell RB, Thalhofer C, et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer[J]. Clin Transl Immunology, 2016, 5(4):e70. |
| [45] | Schütz C, Inselmann S, Sausslele S, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML[J]. Leukemia, 2017, 31(4):829-836. |
| [46] | Ray A, Das DS, Song Y, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells[J]. Leukemia, 2015, 29(6):1441-1444. |
| [47] | Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation[J]. Sci Signal, 2012, 5(230):ra46. |
| [48] | Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation[J]. Nat Commun, 2015, 6:6692. |
| [49] | Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner[J]. J Clin Oncol, 2015, 33(18):2092-2099. |
| [50] | Zitvogel L, Galluzzi L, Kepp O, et al. Type I interferons in anticancer immunity[J]. Nat Rev Immunol, 2015, 15(7):405-414. |
| [51] | Wolchok JD. PD-1 blockers[J]. Cell, 2015, 162(5):937. |
| [52] | Zheng J, Chan PL, Liu Y, et al. ICOS regulates the ge-neration and function of human CD4+ Treg in a CTLA-4 dependent manner[J]. PloS One, 2013, 8(12):e82203. |
| [53] | Huang J, Liu F, Liu Z, et al. Immune checkpoint in glioblastoma: promising and challenging[J]. Front Pharmacol, 2017, 8:242. |
| [54] | Gil M, Komorowski MP, Seshadri M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells[J]. J Immunol, 2014, 193(10):5327-5337. |
| [55] | Filley AC, Dey M. Dendritic cell based vaccination stra-tegy: an evolving paradigm[J]. J Neurooncol, 2017, 133(2):223-235. |
| [1] | 杨盈赤, 庞凯, 张忠涛. 新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(03): 186-189. |
| [2] | 韩序, 王文权, 楼文晖, 刘亮. 免疫检查点抑制剂治疗胃肠胰神经内分泌肿瘤的进展[J]. 外科理论与实践, 2023, 28(03): 267-272. |
| [3] | 邢颖, 程石. 胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114. |
| [4] | 李建芳, 余俊贤, 严超, 朱正纲, 刘炳亚. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(01): 7-16. |
| [5] | 张天羽, 周东, 洪桢. 《儿童抗NMDAR脑炎治疗的国际共识推荐》解读[J]. 诊断学理论与实践, 2022, 21(06): 677-683. |
| [6] | 任佳逸, 糜坚青. 新型抗体类药物在急性B淋巴细胞白血病中的治疗进展[J]. 内科理论与实践, 2022, 17(06): 463-467. |
| [7] | 张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157. |
| [8] | 于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52. |
| [9] | 王思颖，郑幸玲，覃文新. 癌症患者能否长期生存？[J]. 上海交通大学学报, 2021, 55(Sup.1): 49-50. |
| [10] | 宗春燕，沈键锋. 免疫治疗能否治愈肿瘤？[J]. 上海交通大学学报, 2021, 55(Sup.1): 53-54. |
| [11] | 罗雅方, 徐倩玥, 余红. 尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展[J]. 诊断学理论与实践, 2021, 20(06): 592-595. |
| [12] | 苏长青. 从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433. |
| [13] | 周艺, 杨莉. 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413. |
| [14] | 钱梨寒, 沈柏用. 局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446. |
| [15] | 黄轶洲, 钟鸣. 结肠直肠癌B7/CD28家族的研究进展[J]. 外科理论与实践, 2019, 24(05): 470-474. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
